Response to comments on ‘Competing designs for drug combination in phase I dose-finding clinical trials’ by G. Yin, R. Lin and N. Wages
Abstract
As pointed out by Yin and Lin, and Wages, designs for drug-combination trials need to be rigorously evaluated. In our paper, we performed an extensive sensitivity analysis (with some of the results given in the form of additional material), and for each design, we tried to find the best parameter settings for model calibration associated with a high percentage of correct selection (PCS) on average across all scenarios.
Origin : Files produced by the author(s)
Loading...